PRIME Designation Granted Based on Phase 2 ARCHER Trial Results, which Showed Meaningful Preservation of Visual Function in Patients with Geographic Atrophy ANX007 is the First Therapeutic Candidate ...
ANX007 demonstrated significant, broad-based protection from vision loss in foveal and non-foveal patients, and in low light settings ANX007 protected key retinal structures important for vision: ...
BRISBANE, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for patients with ...
WALTHAM, Mass., April 23, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (APLS), a global biopharmaceutical company and leader in complement, today announced post hoc analyses from the ...
Additional data from the Phase 2 ARCHER trial demonstrating protection of visual acuity and anatomical structure following ANX007 treatment will be featured as an oral presentation New preclinical ...
SAN FRANCISCO -- A neuroprotective approach to geographic atrophy (GA) had a time-dependent effect on lesion growth and a significant impact on visual acuity, an early study showed. Overall, the ...
Company Engaging with U.S. and EU Regulatory Authorities to Determine the Optimal Global Pivotal Phase 3 Program for ANX007 The EMA’s PRIME designation provides early and proactive support to ...
Company Engaging with U.S. and EU Regulatory Authorities to Determine the Optimal Global Pivotal Phase 3 Program for ANX007 BRISBANE, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback